. 2006 Jun 12;103(25):9619–9624. doi: 10.1073/pnas.0600966103

Table 1.

Summary of experimental data on nonviral Aβ DNA vaccine therapy against Alzheimer model mice

Exp.	Group	Strain	No. of animals	Start of Tx, mo	Sampling, mo	Duration of Tx, mo	Regimen	Protocol			% Aβ burden (cortex)					% Aβ burden (hippocampus)					Inflammation
Exp.	Group	Strain	No. of animals	Start of Tx, mo	Sampling, mo	Duration of Tx, mo	Regimen	Weekly	Biweekly	Monthly	Fc	IgL	K-Aβ	Emp	No Tx	Fc	IgL	K-Aβ	Emp	No Tx	CD5	Mac3
1	1	Tg	15	4	7	3	Prophylactic	×6	×3		15.5	18.2	31.4	93.1	100	N.T.	N.T.	N.T.	N.T.	N.T.	Neg	Neg
	2	Tg	32	4	9	5	Prophylactic	×6	×8		12.7	13.3	28.1	103	100	N.T.	N.T.	N.T.	N.T.	N.T.	Neg	Neg
	3	Tg	17	4	12	8	Prophylactic	×6	×12		33.7	28.6	51.3	103	100	22	26	65.3	114	100	Neg	Neg
2	1	Tg	20	3	15	12	Prophylactic	×6	×24		30.6	37.2	N.T.	91.2	100	32.5	38.4	N.T.	96	100	Neg	Neg
	2	Tg	16	3	18	15	Prophylactic	×6	×29		38.5	46.2	N.T.	91.3	100	36.4	44.8	N.T.	99.5	100	Neg	Neg
3	1	Tg	23	12	15	3	Therapeutic	×6	×4		42.4	41.6	N.T.	98.1	100	40.3	43.5	N.T.	100	100	Neg	Neg
	2	Tg	19	12	18	6	Therapeutic	×6	×10		47	49.9	N.T.	96.7	100	38	46	N.T.	86.6	100	Neg	Neg
4	1	Tg	18	7	15	8	Therapeutic			×9	67.6	81.7	N.T.	90.6	100	69.4	73.9	N.T.	95.6	100	Neg	Neg
	2	Tg	16	7	18	11	Therapeutic			×12	79.6	88.1	N.T.	91.7	100	74.8	75.6	N.T.	92	100	Neg	Neg
5	1	B6	25	4	7	3	–	×6	×4		N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	Neg	Neg
	2	B6	25	4	9	5	–	×6	×9		N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	Neg	Neg
	3	B6	24	4	12	8	–	×6	×14		N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	N.T.	Neg	Neg

The vaccines were administered for the indicated duration to a large number of mice (176 APP23 and 74 B6 mice). In Exp. 1, the mice were divided into five groups as follows: Aβ-Fc vaccine administration, IgL-Aβ vaccine administration, K-Aβ vaccine administration, empty-vector administration, and no treatment. In Exps. 2–5, the K-Aβ vaccine administration group was excluded from the analysis because of its lower efficacy than other two vaccines. Each group consisted of 4–6 mice. Prophylactic effects were examined in Exps. 1 and 2. Therapeutic effects were examined in Exps. 3 and 4. All APP23 mice were analyzed immunohistochemically with mAb (6F∕3D) against Aβ7-18. Then, the reduction of amyloid plaque was quantified, as shown in Materials and Methods. In Exp. 5, DNA vaccines were administered to B6 mice to know whether the vaccines induce neuroinflammation. Tissues from three mice in each group were immunohistochemically stained with mAbs against CD5 and Mac-3. Neg, negative finding, i.e., no neuroinflammation; N.T., not tested; Exp., experiment; Tx, treatment; Tg, transgenic; Emp, empty vector.